Cardiovascular Health

Experts discuss practice expansion, guideline updates, and team-based care.

Allison Burnett, PharmD, joins The Tell-Tale Heart to break down the first-ever ACC/AHA acute pulmonary embolism guidelines.

Lomitapide demonstrated substantial LDL cholesterol reductions in a pivotal trial.

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.

Explore PREVENT Risk Equations reshaping hypertension care, HFpEF therapy, and CKD-related hyperkalemia.

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

Laxmi Mehta, MD, discusses widespread patient unawareness of nonstatin cholesterol therapies, common statin misconceptions, and the critical role pharmacists play in bridging the lipid treatment knowledge gap.

The guideline establishes a novel clinical classification framework and recommends direct oral anticoagulants over vitamin K antagonists for eligible patients.

Experts Craig Beavers and Kristen Campbell discuss what pharmacists should know heading into ACC 26.

Sarah Nelson, PharmD, highlights how pharmacists are uniquely positioned to prevent heart disease by identifying cardiovascular risk early, improving medication adherence, and addressing lifestyle and social factors.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

Joseph Saseen, PharmD, explains how population health strategies and team-based care create new opportunities for pharmacists to identify lipid treatment gaps and lead evidence-based ASCVD prevention.

Universal aspirin at the first prenatal visit lowers severe preeclampsia rates in high-risk pregnancies, delaying onset without raising hemorrhage or placental abruption risk.

Joseph Saseen, PharmD, highlights how pharmacists can close treatment gaps in dyslipidemia by initiating appropriate statin intensity early, using combination therapy when needed, and proactively assessing adherence.

Host Craig Beavers explores why US blood pressure control still lags despite proven treatments.

Ann Marie Navar, MD, PhD, explains how enlicitide’s sustained LDL-C lowering, favorable tolerability, and structured dosing may improve adherence and expand oral add-on options for patients not at goal on statins.

Sarah Nelson, PharmD, explains how pharmacists can simplify cardiovascular treatment regimens through personalized education, shared decision-making, and cross-sector collaboration to improve adherence and close care gaps in heart disease prevention.

The VESALIUS-CV trial demonstrates that adding evolocumab to maximally tolerated statin therapy significantly reduces major cardiovascular events in both high-risk primary and secondary prevention patients.

Pharmacists drive American Heart Month action by improving adherence, prevention, and equity.

Full results detailing the safety and efficacy of enlicitide decanoate, an oral PCSK9 inhibitor, were published in The New England Journal of Medicine.

During American Heart Month, Sarah Nelson, PharmD, highlights how pharmacists can leverage frequent patient interactions, risk assessment tools, and medication optimization strategies to reduce cardiovascular risk.

Joseph Saseen, PharmD, explains how persistent cholesterol myths undermine care and why emerging oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors could expand access to intensive LDL-C lowering.

Craig Beavers is joined by the investigators of the POLY-HF trial to reinforce the critical role of pharmacist counseling and education in treating patients with heart failure.

A pharmacist-physician model significantly reduces wait times for atrial fibrillation care, enhancing patient access and treatment effectiveness in underserved areas.

Multidisciplinary coordination and streamlined workflows enabled rapid patient access to plozasiran after FDA approval at Stony Brook University Hospital.